S&P Futures
4,155.75-6.75(-0.16%)Dow Futures
33,893.00-30.00(-0.09%)Nasdaq Futures
13,973.75-40.25(-0.29%)
Mind Medicine (MindMed) Inc. (MMEDF)
Chart Events
Performance Outlook
| Previous Close | 2.4300 |
| Open | 2.4500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.4000 - 2.5000 |
| 52 Week Range | 2.2100 - 4.4300 |
| Volume | 860,723 |
| Avg. Volume | 2,951,255 |
| Market Cap | 794.643M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
MindMed Announces the Publication of New Data on Personalized MDMA Dosing
MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions.
- PR Newswire
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) is pleased to announce that it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces and territories of Canada, and a corresponding registration statement on Form F–10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
- PR Newswire
MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31, 2020.
